[uam ad id= 317182 ]
RIO DE JANEIRO, BRAZIL - The Albert Einstein Hospital s Instituto Israelita de Ensino e Pesquisa (Israeli Institute of Teaching and Research) is expected to begin in March Phase 3 trials of the Covaxin vaccine for a period ranging from 45 to 90 days, with results scheduled for May. Approximately 3,000 volunteers will be tested in five reference centers. The vaccine is being developed in India by the Bharat Biotech laboratory.
According to Gláucia Vespa, an immunologist and researcher, Coxavin is an inactivated whole virus vaccine and presents common side effects. Side effects will be determined in the Phase . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here